As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

Considering that drug shortages of semaglutide, liraglutide, and tirzepatide have led to limited access and rising costs, compounded GLP-1 RAs have emerged as a workaround. However, these non-FDA ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...